No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
No Data
Rising Drug Costs Force a Third of Americans to Leave Prescriptions Unfilled: Report
J&J Talc Claimants Lose Bid to Block Bankruptcy Bid
J&J Reports Positive Phase 3 Data for Nipocalimab for Neuromuscular Disease
Johnson & Johnson Reports 'Positive' Results in Late-Stage Myasthenia Gravis Trial
Express News | J&J - Papillon Study Met Its Primary Endpoint
Express News | Rybrevant®▼ (Amivantamab) in Combination With Chemotherapy Is First Therapy Approved by European Commission for First-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer With Activating Egfr Exon 20 Insertion Mutations